Fig. 2From: Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in GermanyCharacterization of the response to treatment in all erenumab responders since availability of erenumab from the physicians’ perspectives. N = 42 (number of physicians); QoL=quality of life (e.g., Headache Intensity Test, evaluated on a five-point Likert scale: HIT-6); MMD=monthly migraine days. *Accompanying factors include aura, sensitivity for light and noise, nausea and allodyniaBack to article page